Lead Product(s) : Entospletinib,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GS-9973 (entospletinib) is a selective inhibitor targeting spleen tyrosine kinase (SYK), a critical node in a dysregulated transcription regulatory network within AML defined by persistent high expression of the transcription factors HOXA9 and MEIS1.
Product Name : GS-9973
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Entospletinib,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entospletinib,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First poster describes the analysis of mutational and gene expression signatures from bone marrow and peripheral blood samples of patients with NPM1-mutated AML, with or without co-mutation of FLT3, is a strong predictor of GS-9973 (entospletinib) anti-l...
Product Name : GS-9973
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : Entospletinib,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entospletinib,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Jefferies LLC
Deal Size : $155.0 million
Deal Type : Private placement
Kronos Bio Announces $155 Million Private Financing
Details : This capital will help advance company's lead spleen tyrosine kinase (SYK) inhibitor, which we recently acquired from Gilead, including potentially into a registrational trial in 2021.
Product Name : GS-9973
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 24, 2020
Lead Product(s) : Entospletinib,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Jefferies LLC
Deal Size : $155.0 million
Deal Type : Private placement
Lead Product(s) : Entospletinib,Cytarabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Kronos Bio
Deal Size : Undisclosed
Deal Type : Agreement
Bischofberger's Kronos Buys SYK Inhibitors from Gilead
Details : The portfolio includes the clinical stage compounds entospletinib, which has been evaluated in Phase 1 and Phase 2 clinical trials in oncology patients, and lanraplenib, which has been evaluated in Phase 2 clinical trials in patients with autoimmune dise...
Product Name : GS-9973
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 16, 2020
Lead Product(s) : Entospletinib,Cytarabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Kronos Bio
Deal Size : Undisclosed
Deal Type : Agreement